SCHEMBL6505968

SCHEMBL6505968

O=CC(c1cccnc1)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.49
CYP2D6 P10635 5/20 0.49
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 4/20 0.49
SLC6A3 Q01959 4/20 0.49
KCNH2 Q12809 3/20 0.49
CYP19A1 P11511 2/20 0.45
CYP17A1 P05093 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
CFTR P13569 1/20 0.42
GOPC Q9HD26 1/20 0.42
CYP1A1 P04798 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP1B1 Q16678 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28154217 0.83 UGT2B7 (0.50) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL6410479 0.83 SLC6A2 (0.46) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL360712 0.82 CFTR (0.57) SLC6A2SLC6A4SLC6A3KCNH2CYP19A1
SCHEMBL1515810 0.82 UGT2B7 (0.46) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL1515814 0.82 ROCK2 (0.47) CYP3A4
SCHEMBL3903975 0.77 CYP11B1 (0.44) SLC6A2SLC6A4SLC6A3CYP19A1CYP11B1
SCHEMBL6501170 0.77 CYP19A1 (0.46) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL1515839 0.77 KCNA5 (0.47) CYP3A4CYP2D6CYP19A1CYP17A1CYP11B1
SCHEMBL6502611 0.76 POLB (0.51) SLC6A2SLC6A4SLC6A3KCNH2CYP19A1
SCHEMBL6503338 0.76 CYP19A1 (0.62) CYP3A4SLC6A2SLC6A4SLC6A3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CYP3A4 4806/4885CYP2D6 4399/4885SLC6A2 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.